ANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

Several other brokerages have also commented on ANIP. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Guggenheim increased their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $79.17 on Wednesday. The business’s 50-day moving average price is $76.15 and its two-hundred day moving average price is $82.08. ANI Pharmaceuticals has a twelve month low of $56.71 and a twelve month high of $99.50. The stock has a market cap of $1.77 billion, a P/E ratio of 23.58 and a beta of 0.44. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,312 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the sale, the chief financial officer directly owned 185,543 shares in the company, valued at approximately $14,008,496.50. This trade represents a 3.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $77.95, for a total value of $38,975.00. Following the completion of the sale, the vice president owned 78,890 shares in the company, valued at approximately $6,149,475.50. This represents a 0.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 27,860 shares of company stock worth $2,111,581. Corporate insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently made changes to their positions in ANIP. Divisadero Street Capital Management LP purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $21,454,000. Assenagon Asset Management S.A. lifted its stake in shares of ANI Pharmaceuticals by 259.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock valued at $4,244,000 after purchasing an additional 33,438 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $1,597,000. Apis Capital Advisors LLC lifted its stake in shares of ANI Pharmaceuticals by 28.1% in the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after purchasing an additional 36,000 shares during the period. Finally, Decker Retirement Planning Inc. lifted its stake in shares of ANI Pharmaceuticals by 76,862.5% in the 3rd quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after purchasing an additional 36,894 shares during the period. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.